Abstract
Oxaliplatin is a highly neurotoxic chemotherapeutic agent routinely used for the treatment of colorectal cancer. Recent data suggest that oxaliplatin-induced peripheral neuropathy may be long-lasting; however, the effects of persistent neuropathy on colorectal cancer survivors’ physical and emotional well-being are not well understood. This cross sectional, descriptive study included persons who had received oxaliplatin-based chemotherapy for treatment of colorectal cancer at Moffitt Cancer Center between 2003 and 2010. Questionnaires including the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool, Center for Epidemiological Studies Depression Scale (CES-D), Insomnia Severity Index, Medical Outcomes Study Short Form 36, and a demographic survey were administered. Pearson’s correlations and linear regression analyses were used to examine relationships between neuropathy and depressive symptoms, sleep quality, and health-related quality of life (HRQOL). Eighty-nine percent of participants reported at least one symptom of peripheral neuropathy with a mean of 3.8 (±2.4) neuropathic symptoms. Depressive symptoms on the CES-D were significantly associated with more severe peripheral neuropathy(r = 0.38, p = 0.0001) and interference with activities (r = 0.59, p < 0.0001). Higher degrees of sleep disturbance on the Insomnia Severity Index (ISI) were significantly associated with more severe peripheral neuropathy (r = 0.35, p = 0.0004) and interference with activities(r = 0.52, p < 0.0001). HRQOL was significantly associated with peripheral neuropathy and interference with activities.
Similar content being viewed by others
References
ACS (2012) Cancer facts & figures 2012; Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf. Accessed June 2012
NCI (2010) FDA Approval for Oxaliplatin; Available from: http://www.cancer.gov/cancertopics/druginfo/fda-oxaliplatin. Accessed June 2012
NCI (2012) Surveillance epidemiology and end results stat fact sheets; Available from: http://seer.cancer.gov/statfacts/html/colorect.html. Accessed June 2012
Tofthagen C (2010) Surviving chemotherapy for colon cancer and living with the consequences. J Palliat Med 13(11):1389–1391
Krishnan A et al (2005) Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 32:51–60
Choi J et al (2006) Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer. Anticancer Drugs 17(1):103–105
Park SB et al (2011) Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 16(5):708–716
Pietrangeli A et al (2006) Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 56(1):13–16
Kautio A et al (2008) Amitriptyline in the treatment of chemotherapy induced neuropathic symptoms. J Pain Symptom Manage 35(1):31–39
Kopec J et al (2006) Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. J Support Oncol 4(8):W1–W8
Tofthagen C (2010) Patient perceptions associated with chemotherapy induced peripheral neuropathy. Clin J Oncol Nurs 14(3):E22–E28
Gore M et al (2005) Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 30(4):374–385
Gore M et al (2006) Burden of illness in painful diabetic peripheral neuropathy: the patients’ perspectives. J Pain 7(12):892–900
Zelman DC, Brandenburg NA, Gore M (2006) Sleep impairment in patients with painful diabetic peripheral neuropathy. Clin J Pain 22(8):681–685
Almadrones L et al (2004) Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study. Oncol Nurs Forum 31(3):615–623
Bakitas MA (2007) Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res 56(5):323–331
Ostchega Y, Donohue M, Fox N (1988) High-dose cisplatin-related peripheral neuropathy. Cancer Nurs 11(1):23–32
Tofthagen CS, McMillan SC, Kip KE (2011) Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Cancer Nurs 34(4):E10–E20
Radloff LS (1977) The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Meas 1:385–401
Lewinsohn PM et al (1997) Center for epidemiologic studies depression scale (CES-D) as a screening instrument for depression among community-residing older adults. Psychol Aging 12(2):277–287
Morin CM (1993) Insomnia: psychological assessment and management. Guilford Press, New York
Savard MH et al (2005) Empirical validation of the insomnia severity index in cancer patients. Psychooncology 14(6):429–441
Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473–483
Dunlap B, Paice JA (2006) Chemotherapy-induced peripheral neuropathy: a need for standardization in measurement. J Support Oncol 4(8):398–399
Cavaletti G et al (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 24(2):454–462
Postma TJ et al (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135–1139
Adams RA et al (2011) Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 12(7):642–653
Argyriou AA et al (2013) Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer 119(2):438–444
Argyriou AA et al (2012) Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 23(12):3116–3122
Oshinaike O et al (2012) Influence of age and neurotoxic HAART use on frequency of HIV sensory neuropathy. AIDS Research and Treatment 2012:961510
Argyriou AA et al (2006) Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer 14(3):223–229
Alejandro LM et al (2012) Predicting acute and persistent neuropathy associated with oxaliplatin. Am J Clin Oncol. doi:10.1097/COC.0b013e318246b50d
Lecomte T et al (2006) Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res: Off J Am Assoc Cancer Res 12(10):3050–3056
Ruzzo A et al (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol: Off J Am Soc Clin Oncol 25(10):1247–1254
Gamelin L et al (2007) Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res: Off J Am Assoc Cancer Res 13(21):6359–6368
Cavaletti G, Alberti P, Marmiroli P (2011) Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol 12(12):1151–1161
Conflict of interest
The primary author reports no conflict of interest, has full control of all primary data and agrees to allow the journal to review the data if requested.
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was supported by a University of South Florida Nursing Faculty in Pilot Research Projects Grant and the University of Massachusetts Boston–Dana Farber /Harvard Cancer Center U54 Cancer Research Partnership.
Rights and permissions
About this article
Cite this article
Tofthagen, C., Donovan, K.A., Morgan, M.A. et al. Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer 21, 3307–3313 (2013). https://doi.org/10.1007/s00520-013-1905-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-013-1905-5